(Q37249719)

19 August 2017

1 reference

title

Treatment of leishmaniasis with miltefosine: 2008 status (English)

1 reference

19 August 2017

1 reference

Jonathan Josh Berman

1

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 September 2008

1 reference

Expert Opinion on Drug Metabolism & Toxicology

19 August 2017

published in

1 reference

19 August 2017

volume

4

1 reference

19 August 2017

issue

9

1 reference

19 August 2017

page(s)

1209-1216

1 reference

Miltefosine to treat leishmaniasis

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Liposomal amphotericin B for the treatment of visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Injectable paromomycin for Visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

The activity of alkyl phosphorylcholines and related derivatives against Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

The activities of four anticancer alkyllysophospholipids against Leishmania donovani, Trypanosoma cruzi and Trypanosoma brucei

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

In vitro bactericidal activity of the antiprotozoal drug miltefosine against Streptococcus pneumoniae and other pathogenic streptococci

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

In vitro activities of miltefosine and two novel antifungal biscationic salts against a panel of 77 dermatophytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Hexadecylphosphocholine (miltefosine) has broad-spectrum fungicidal activity and is efficacious in a mouse model of cryptococcosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Characterisation of Leishmania donovani promastigotes resistant to hexadecylphosphocholine (miltefosine).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Leishmania donovani resistance to miltefosine involves a defective inward translocation of the drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Phospholipid translocation and miltefosine potency require both L. donovani miltefosine transporter and the new protein LdRos3 in Leishmania parasites.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Functional cloning of the miltefosine transporter. A novel P-type phospholipid translocase from Leishmania involved in drug resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Miltefosine affects lipid metabolism in Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Miltefosine (hexadecylphosphocholine) inhibits cytochrome c oxidase in Leishmania donovani promastigotes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Possible mechanism of miltefosine-mediated death of Leishmania donovani

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Lysosomal and mitochondrial pathways in miltefosine-induced apoptosis in U937 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Pharmacokinetics of miltefosine in Old World cutaneous leishmaniasis patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Inward translocation of the phospholipid analogue miltefosine across Caco-2 cell membranes exhibits characteristics of a carrier-mediated process

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Oral miltefosine for Indian visceral leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Efficacy and tolerability of miltefosine for childhood visceral leishmaniasis in India

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Miltefosine in children with visceral leishmaniasis: a prospective, multicentric, cross-sectional study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Efficacy and toxicity of sodium stibogluconate for mucosal leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Efficacy of sodium stibogluconate alone and in combination with allopurinol for treatment of mucocutaneous leishmaniasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Comparison of miltefosine and meglumine antimoniate for the treatment of zoonotic cutaneous leishmaniasis (ZCL) by a randomized clinical trial in Iran

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

First case of typical Old World cutaneous leishmaniasis treated with miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Diffuse cutaneous leishmaniasis responds to miltefosine but then relapses.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Cure of antimony-unresponsive Indian post-kala-azar dermal leishmaniasis with oral miltefosine

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Successful treatment with miltefosine of disseminated cutaneous leishmaniasis in a severely immunocompromised patient infected with HIV-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

Aminosidine (paromomycin) versus sodium stibogluconate for the treatment of American cutaneous leishmaniasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F17425255.4.9.1209

10.1517/17425255.4.9.1209

21 January 2018

Identifiers

DOI

1 reference

19 August 2017

1 reference